|
I know that this study was small with only 30 patients, but to have a 90% response rate, and 83% complete remission rate after 2 cycles is rather astonishing. The best news in this is that after a median of 32 months, 53% of the patients are still in complete remission, which is a remarkably good number for the risk characteristics of this patient cohort.
The basics here:
30 patients enrolled
17 reached CR after 1st round of decitabine + induction chemo
8 reached CR after 2nd round of decitabine + induction chemo
3 went on to transplant and died as a result of complications
16 are still in complete remission at a median of 32 months later
Since AML and MDS have very similar resistance to treatment, I am wondering if this is being tried anywhere for MDS. (i could not find it in any clinical trials) It appears as if this is bringing AML closer to non-HCT cure....any other thoughts?
__________________
MDS RCMD w/grade 2-3 fibrosis. Allo-MUD Feb 26, 2014. Relapsed August 2014. Free and clear of MDS since November 2014 after treatment with Vidaza and Rituxan. Experiencing autoimmune attack on CNS thought to be GVHD, some gut, skin and ocular cGVHD. Neuropathy over 80% of body.
|